glp-1 receptor agonists blindness risk as Treatments for Type 2 Diabetes Doctor Explains GLP 1 Blindness
Description
Liu Z, Yang H, Zhi L, et al
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9) Diabetes Obes Metab
This results in a reduction in calorie intake and weight loss
These agents can promote vascular function by vasodilation and improve endothelial function by enhancing nitric oxide production [3, 6, 7]
